VNDA
Vanda Pharmaceuticals Inc.
Biotechnology · Healthcare · United States
4.05
close · 2026-10-29
value
91
cheaper than peers91
quality
32
stronger fundamentals32
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 1.12× | 97 |
| price to book | 0.73× | 90 |
| forward P/E | 20.25× | 57 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 10.4% | 59 |
| operating margin | -126.3% | 52 |
| return on equity | -77.8% | 33 |
| revenue growth | -3.9% | 32 |
4 of 4 measures available
Facts
| market cap | $245M |
| free cash flow | -$86.7M |
| employees | 533 |
| first trade | 2006-04-12 |
| next earnings | 2026-10-28 |
| fundamentals updated | 2026-10-28 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.74 | -0.33 | 0.04 | 0.11 |
| free cash flow | -$110.4M | -$16.2M | $12.4M | $31.3M |
| net income | -$220.5M | -$18.9M | $2.5M | $6.3M |
| revenue | $216.1M | $198.8M | $192.6M | $254.4M |